Quantcast
Last updated on April 19, 2014 at 1:20 EDT

Latest Non-Hodgkin lymphoma Stories

2014-02-03 10:31:39

Immune cells undergo 'spontaneous' changes on a daily basis that could lead to cancers if not for the diligent surveillance of our immune system, Melbourne scientists have found. The research team from the Walter and Eliza Hall Institute found that the immune system was responsible for eliminating potentially cancerous immune B cells in their early stages, before they developed into B-cell lymphomas (also known as non-Hodgkin's lymphomas). The results of the study were published today in...

2014-01-24 12:23:26

SAN DIEGO, Jan. 24, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission approve Roche's subcutaneous (SC) formulation of MabThera(®) (rituximab) using Halozyme's recombinant human hyaluronidase (rHuPH20) for the treatment of patients with common forms of non-Hodgkin lymphoma (NHL). (Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)...

2014-01-06 04:21:41

- PIXUVRI Deemed Cost Effective for Patients with Multiply Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (NHL) - SEATTLE, Jan. 6, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported that the National Institute for Health and Care Excellence (NICE), the independent body responsible for driving improvement and excellence in the health and social care system in the United Kingdom (UK), has issued its Final Appraisal Determination...

2013-12-04 04:21:20

- Decision Applies to Patients with Aggressive B-cell Non-Hodgkin Lymphoma Who Have Failed Two or Three Prior Lines of Therapy - SEATTLE, Dec. 4, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that it concluded an agreement with the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) in Germany for PIXUVRI® (pixantrone). PIXUVRI is the first medicinal product approved in the European Union (E.U.) for patients with...

2013-11-21 16:26:24

Proceeds of Sale of Jacques Lowe Photographs of Former First Lady Jacqueline Kennedy to Benefit LLS Mission WHITE PLAINS, N.Y., Nov. 21, 2013 /PRNewswire/ -- A striking collection of framed photographs owned by The Leukemia & Lymphoma Society (LLS) of former First Lady Jacqueline Kennedy, both alone and accompanied by President John Kennedy, and other family members, is part of a major auction taking place in Amesbury, Mass., to commemorate the 50(th) anniversary of the...

2013-11-07 04:24:12

THOUSAND OAKS, Calif., Nov. 7, 2013 /PRNewswire/ -- ImmunGene, Inc., a biotechnology company focused on developing antibody-cytokine fusion technology therapies to treat cancer, today announced it has secured $9 million in a milestone-based Series A financing from Ally Bridge Group. Previous investments in the Company were converted into Series A preferred stock. ImmunGene will use the capital to advance its early-stage development products to IND-enabling studies. "ImmunGene, run by...

2013-10-15 04:21:01

SEATTLE, Oct. 15, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that the National Institute for Health and Care Excellence (NICE), a non-departmental public body of the Department of Health in the United Kingdom (UK), issued second draft guidance on PIXUVRI(®) (pixantrone) as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (aggressive B-cell NHL). NICE's...

2013-09-26 12:30:02

John Theurer Cancer Center Chairman and Lymphoma Chief Andre Goy, M.D., M.S., Continues to Lead Advances in MCL Research and Treatment HACKENSACK, N.J., Sept. 26, 2013 /PRNewswire/ -- Andre Goy, M.D., M.S., Chairman and Director of John Theurer Cancer Center and Chief of the Lymphoma Program, has just published two important papers in relapsed/refractory mantle-cell lymphoma (MCL) in the Journal of Clinical Oncology and New England Journal of Medicine. MCL is a difficult subtype...

2013-09-12 16:27:29

-- Company Secures Total of $2.5 Million with Final Close of Series A Financing -- MENLO PARK, Calif., Sept. 12, 2013 /PRNewswire/ -- Bullet Biotechnology, Inc., a company developing an active immunotherapy for B-cell lymphomas, announced that it completed the final close of its Series A financing in June, bringing the total amount raised since the company's founding in September 2011 to approximately $2.5 million. The additional Series A funding will be used to support additional...

2013-08-29 08:24:27

Priority Review Granted SUNNYVALE, Calif., Aug. 29, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) for the investigational oral Bruton's tyrosine kinase (BTK) inhibitor ibrutinib, for two B-cell malignancy indications: previously treated mantle cell lymphoma (MCL) and previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)....